Trépanier E F, Nafziger A N, Amsden G W
Department of Pharmacy Services, Bassett Healthcare, Cooperstown, New York 13326-1394, USA.
Antimicrob Agents Chemother. 1998 Mar;42(3):695-7. doi: 10.1128/AAC.42.3.695.
Twelve healthy volunteers were enrolled in an open-label, randomized, crossover study. Subjects received single doses of theophylline (5 mg/kg) with and without multiple-dose terbinafine, and 11 blood samples were collected over 24 h. The study phases were separated by a 4-week washout period. Theophylline serum data were modeled via noncompartmental analysis. When the control phase (i.e., no terbinafine) was compared to the treatment phase (terbinafine), theophylline exposure (the area under the serum concentration-time curve from time zero to infinity) increased by 16% (P = 0.03), oral clearance decreased by 14% (P = 0.04), and half-life increased by 24% (P = 0.002). No significant changes in other theophylline pharmacokinetic parameters were evident.
12名健康志愿者参与了一项开放标签、随机、交叉研究。受试者接受了单剂量的茶碱(5毫克/千克),分别在服用和未服用多剂量特比萘芬的情况下,并在24小时内采集了11份血样。研究阶段之间有4周的洗脱期。茶碱血清数据通过非房室分析进行建模。当将对照阶段(即未使用特比萘芬)与治疗阶段(使用特比萘芬)进行比较时,茶碱暴露量(血清浓度-时间曲线从零到无穷大的面积)增加了16%(P = 0.03),口服清除率降低了14%(P = 0.04),半衰期增加了24%(P = 0.002)。其他茶碱药代动力学参数无明显显著变化。